This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThromboGenics Business Update


ThromboGenics Business Update

  • In February, the Board of Directors of ThromboGenics decided to explore strategic options for the Company. This decision is intended to increase the Company's ability to realize the significant commercial potential of JETREA ® (ocriplasmin) in the US, and to fully capitalize on the Company's proven product development capabilities
  • The strategic review is ongoing. An update will be provided in due course

  • Cash of €156.9 million on hand at the end of March 2014, compared to €172.4 million at the end of December 2013

JETREA ® in the US                       
  • The Company's US organization continues to focus on establishing JETREA ® as an earlier treatment for patients with symptomatic vitreomacular adhesion (VMA)
  • New efficacy and safety data presented at The Association for Research in Vision and Ophthalmology (ARVO) in May 2014 highlighted real-world experience with JETREA ®. These showed positive outcomes, and a safety profile in line with the Phase III clinical program
  • 65 centers are now recruiting patients in the ORBIT (Ocriplasmin Research to Better Inform Treatment) Phase IV post marketing study
  • A permanent J-Code for JETREA ® has been in place since January 1 2014


The Transparency Commission of the  French National Health Authority issued a positive opinion for the reimbursement and hospital listing of JETREA ® by the French National Health Insurance in January  
  • In March, JETREA ®  was approved by Swissmedic for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns
  • In April, JETREA ® was approved in Malaysia for the same indication, the product's first approval in Asia

Leuven, Belgium, May 22, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issued a business update for the three month period ending 31 March 2014.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs